What is the recommended dosage of Tamiflu (oseltamivir) for pediatric patients with influenza?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pediatric Tamiflu (Oseltamivir) Dosing

Oseltamivir dosing in children is weight-based for those ≥12 months and age/weight-based for infants, with treatment initiated within 48 hours of symptom onset for 5 days at twice-daily dosing, and prophylaxis given once daily for 10 days. 1, 2

Treatment Dosing (5 days, twice daily)

Children ≥12 months to 12 years (Weight-Based)

  • ≤15 kg (≤33 lb): 30 mg (5 mL) twice daily 1, 3
  • >15-23 kg (>33-51 lb): 45 mg (7.5 mL) twice daily 1, 3
  • >23-40 kg (>51-88 lb): 60 mg (10 mL) twice daily 1, 3
  • >40 kg (>88 lb): 75 mg (12.5 mL) twice daily 1, 3

Infants <12 months (Age-Based)

  • 9-11 months: 3.5 mg/kg per dose twice daily 1, 2
  • Term infants 0-8 months: 3 mg/kg per dose twice daily 1, 2

Preterm Infants (Postmenstrual Age-Based)

Preterm infants require substantially lower doses due to immature renal function: 1, 2

  • <38 weeks postmenstrual age: 1.0 mg/kg twice daily 1, 2
  • 38-40 weeks postmenstrual age: 1.5 mg/kg twice daily 1, 2
  • >40 weeks postmenstrual age: 3.0 mg/kg twice daily 1, 2

Prophylaxis Dosing (10 days, once daily)

Children ≥12 months (Weight-Based)

Use the same weight-based doses as treatment, but once daily instead of twice daily for 10 days: 1, 2

  • ≤15 kg: 30 mg (5 mL) once daily 1
  • >15-23 kg: 45 mg (7.5 mL) once daily 1
  • >23-40 kg: 60 mg (10 mL) once daily 1
  • >40 kg: 75 mg (12.5 mL) once daily 1

Infants 3-11 months

  • 3 mg/kg once daily for 10 days 1, 2
  • Prophylaxis is NOT recommended for infants <3 months unless the situation is judged critical due to limited safety and efficacy data 1

Who Should Receive Treatment

Regardless of vaccination status, treat the following children as early as possible: 1

  • All children hospitalized with suspected influenza 1
  • Children with severe, complicated, or progressive illness attributable to influenza, regardless of symptom duration 1
  • Children at high risk for complications (age <2 years, chronic medical conditions including asthma, cardiac disease, diabetes, immunodeficiency) 1

Consider treatment for: 1

  • Any otherwise healthy child with suspected influenza, especially if treatment can start within 48 hours 1
  • Children whose household contacts are <6 months old or have high-risk conditions 1

Critical Timing Considerations

Treatment provides maximum benefit when started within 48 hours of symptom onset, reducing illness duration by 1-1.5 days (26-36% reduction) and decreasing complications including acute otitis media by 34-44%. 1, 2, 4

However, treatment after 48 hours still provides substantial benefit in hospitalized children and those with moderate-to-severe or progressive disease, and should be strongly considered. 1

For prophylaxis, initiate within 48 hours following close contact with an infected individual. 2, 5

Renal Impairment Adjustments

For patients with creatinine clearance 10-30 mL/min: 1

  • Treatment: 75 mg once daily (instead of twice daily) for 5 days 1
  • Prophylaxis: 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 total doses) 1

Formulation and Administration

Oseltamivir is available as: 1, 3

  • Capsules: 30 mg, 45 mg, 75 mg 1, 3
  • Oral suspension: 6 mg/mL concentration when reconstituted 1, 3

If commercial suspension is unavailable, capsules can be opened and contents mixed with simple syrup or Ora-Sweet SF by retail pharmacies to achieve 6 mg/mL concentration. 1

Administration with food significantly reduces nausea and vomiting (occurring in ~10-15% of children), which are the most common adverse effects. 1, 5

Common Pitfalls to Avoid

  • Do not withhold treatment while awaiting laboratory confirmation in high-risk patients, as rapid antigen tests have poor sensitivity 1, 2
  • Do not refuse treatment after 48 hours in hospitalized or severely ill children—benefits persist even with delayed initiation 1
  • Do not use adult dosing in children >40 kg who are <13 years old—use weight-based pediatric dosing 1
  • Do not forget to adjust doses in preterm infants based on postmenstrual age, not just weight, to avoid toxicity 1, 2
  • Do not use prophylaxis in infants <3 months unless the clinical situation is critical 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Oseltamivir Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010

Guideline

Oseltamivir Dosage and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.